Cardio-Oncology Training: A Proposal From the International Cardioncology Society and Canadian Cardiac Oncology Network for a New Multidisciplinary Specialty


      There is an increasing awareness and clinical interest in cardiac safety during cancer therapy as well as in optimally addressing cardiac issues in cancer survivors. Although there is an emerging expertise in this area, known as cardio-oncology, there is a lack of organization in the essential components of contemporary training. This proposal, an international consensus statement organized by the International Cardioncology Society and the Canadian Cardiac Oncology Network, attempts to marshal the important ongoing efforts for training the next generation of cardio-oncologists. The necessary elements are outlined, including the expectations for exposure necessary to develop adequate training. There should also be a commitment to local, regional, and international education and research in cardio-oncology as a requirement for advancement in the field.

      Key Words

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Journal of Cardiac Failure
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Herrmann J.
        • Lerman A.
        • Sandhu N.P.
        • Villarraga H.R.
        • Mulvagh S.L.
        • Kohli M.
        Evaluation and management of patients with heart disease and cancer: cardio-oncology.
        Mayo Clin Proc. 2014; 89: 1287-1306
        • Lenihan D.J.
        • Cardinale D.
        • Cipolla C.M.
        The compelling need for a cardiology and oncology partnership and the birth of the International Cardioncology Society.
        Prog Cardiovasc Dis. 2010; 53: 88-93
        • Lenihan D.J.
        • Cardinale D.M.
        Late cardiac effects of cancer treatment.
        J Clin Oncol. 2012; 30: 3657-3664
        • Bowles E.J.
        • Wellman R.
        • Feigelson H.S.
        • Onitilo A.A.
        • Freedman A.N.
        • Delate T.
        • et al.
        Risk of heart failure in breast cancer patients after anthracycline and trastuzumab treatment: a retrospective cohort study.
        J Natl Cancer Inst. 2012; 104: 1293-1305
        • Edwards B.K.
        • Noone A.M.
        • Mariotto A.B.
        • Simard E.P.
        • Boscoe F.P.
        • Henley S.J.
        • et al.
        Annual report to the nation on the status of cancer, 1975–2010, featuring prevalence of comorbidity and impact on survival among persons with lung, colorectal, breast, or prostate cancer.
        Cancer. 2014; 120: 1290-1314
        • Koelwyn G.J.
        • Khouri M.
        • Mackey J.R.
        • Douglas P.S.
        • Jones L.W.
        Running on empty: cardiovascular reserve capacity and late effects of therapy in cancer survivorship.
        J Clin Oncol. 2012; 30: 4458-4461
        • Hasin T.
        • Gerber Y.
        • McNallan S.M.
        • Weston S.A.
        • Kushwaha S.S.
        • Nelson T.J.
        • et al.
        Patients with heart failure have an increased risk of incident cancer.
        J Am Coll Cardiol. 2013; 62: 881-886
        • Steingart R.M.
        • Bakris G.L.
        • Chen H.X.
        • Chen M.-H.
        • Force T.
        • Ivy S.P.
        • et al.
        Management of cardiac toxicity in patients receiving vascular endothelial growth factor signaling pathway inhibitors.
        Am Heart J. 2012; 163: 156-163
        • Groarke J.D.
        • Choueiri T.K.
        • Slosky D.
        • Cheng S.
        • Moslehi J.
        Recognizing and managing left ventricular dysfunction associated with therapeutic inhibition of the vascular endothelial growth factor signaling pathway.
        Curr Treat Options Cardiovasc Med. 2014; 16: 335
        • Grandin W.
        • Ky B.
        • Cornell R.F.
        • Carver J.
        • Lenihan D.J.
        Patterns of cardiac toxicity associated with irreversible proteasome inhibition in the treatment of multiple myeloma.
        J Card Fail. 2014; 21: 138-144
        • Albini A.
        • Pennesi G.
        • Donatelli F.
        • Cammarota R.
        • de Flora S.
        • Noonan D.M.
        Cardiotoxicity of anticancer drugs: the need for cardio-oncology and cardio-oncological prevention.
        J Natl Cancer Inst. 2010; 102: 14-25
        • Hudson M.M.
        • Ness K.K.
        • Gurney J.G.
        • Mulrooney D.A.
        • Chemaitilly W.
        • Krull K.R.
        • et al.
        Clinical ascertainment of health outcomes among adults treated for childhood cancer.
        JAMA. 2013; 309: 2371-2381
        • Armstrong G.T.
        • Chen Y.
        • Yasui Y.
        • Leisenring W.
        • Gibson T.M.
        • Mertens A.C.
        • et al.
        Reduction in late mortality among 5-year survivors of childhood cancer.
        N Engl J Med. 2016; 374: 833-842
        • Groarke J.D.
        • Nguyen P.L.
        • Nohria A.
        • Ferrari R.
        • Cheng S.
        • Moslehi J.
        Cardiovascular complications of radiation therapy for thoracic malignancies: the role for non-invasive imaging for detection of cardiovascular disease.
        Eur Heart J. 2014; 35: 612-623
        • Ammon M.
        • Arenja N.
        • Leibundgut G.
        • Buechel R.R.
        • Kuster G.M.
        • Kaufmann B.A.
        • et al.
        Cardiovascular management of cancer patients with chemotherapy-associated left ventricular systolic dysfunction in real-world clinical practice.
        J Card Fail. 2013; 19: 629-634
        • Thakur A.
        • Witteles R.M.
        Cancer therapy–induced left ventricular dysfunction: interventions and prognosis.
        J Card Fail. 2014; 20: 155-158
        • Armstrong G.T.
        • Oeffinger K.C.
        • Chen Y.
        • Kawashima T.
        • Yasui Y.
        • Leisenring W.
        • et al.
        Modifiable risk factors and major cardiac events among adult survivors of childhood cancer.
        J Clin Oncol. 2013; 31: 3673-3680
        • Lenihan D.J.
        Cardiac biomarkers, cardiotoxicity, and active collaboration: is this the final frontier or the wave we should catch?.
        J Am Coll Cardiol. 2014; 63: 817-818
        • Cardinale D.
        • Colombo A.
        • Bacchiani G.
        • Tedeschi I.
        • Meroni C.A.
        • Veglia F.
        • et al.
        Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy.
        Circulation. 2015; 131: 1981-1988
        • Ewer M.S.
        • Vooletich M.T.
        • Durand J.B.
        • Woods M.L.
        • Davis J.R.
        • Valero V.
        • et al.
        Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment.
        J Clin Oncol. 2005; 23: 7820-7826
        • Yoon G.J.
        • Telli M.L.
        • Kao D.P.
        • Matsuda K.Y.
        • Carlson R.W.
        • Witteles R.M.
        Left ventricular dysfunction in patients receiving cardiotoxic cancer therapies are clinicians responding optimally?.
        J Am Coll Cardiol. 2010; 56: 1644-1650
        • Khouri M.G.
        • Douglas P.S.
        • Mackey J.R.
        • Martin M.
        • Scott J.M.
        • Scherrer-Crosbie M.
        • et al.
        Cancer therapy-induced cardiac toxicity in early breast cancer: addressing the unresolved issues.
        Circulation. 2012; 126: 2749-2763
        • Cote G.M.
        • Sawyer D.B.
        • Chabner B.A.
        ERBB2 inhibition and heart failure.
        N Engl J Med. 2012; 367: 2150-2153
        • Armstrong G.T.
        • Joshi V.M.
        • Zhu L.
        • Srivastava D.
        • Zhang N.
        • Ness K.K.
        • et al.
        Increased tricuspid regurgitant jet velocity by Doppler echocardiography in adult survivors of childhood cancer: a report from the St Jude Lifetime Cohort Study.
        J Clin Oncol. 2013; 31: 774-781
        • Konstam M.A.
        • Executive Council of the Heart Failure Society of America
        Heart failure training: a call for an integrative, patient-focused approach to an emerging cardiology subspecialty.
        J Am Coll Cardiol. 2004; 44: 1361-1362
        • Young J.B.
        • Abraham W.T.
        • Bourge R.C.
        • Konstam M.A.
        • Stevenson L.W.
        • Heart Failure Society of America
        Task Force 8: Training in Heart Failure endorsed by the Heart Failure Society of America.
        J Am Coll Cardiol. 2008; 51: 383-389
        • Palaniswamy C.
        Milestones and the next accreditation system: what does it mean to the fellows?.
        J Am Coll Cardiol. 2014; 64: 1178-1180
        • Seicean S.
        • Seicean A.
        • Alan N.
        • Plana J.C.
        • Budd G.T.
        • Marwick T.H.
        Cardioprotective effect of beta-adrenoceptor blockade in patients with breast cancer undergoing chemotherapy: follow-up study of heart failure.
        Circ Heart Fail. 2013; 6: 420-426
        • Seicean S.
        • Seicean A.
        • Plana J.C.
        • Budd G.T.
        • Marwick T.H.
        Effect of statin therapy on the risk for incident heart failure in patients with breast cancer receiving anthracycline chemotherapy: an observational clinical cohort study.
        J Am Coll Cardiol. 2012; 60: 2384-2390
        • Fleming L.M.
        Subspecialist scholarship in quality improvement.
        J Am Coll Cardiol. 2014; 64: 1064-1065
        • Negishi K.
        • Negishi T.
        • Haluska B.A.
        • Hare J.L.
        • Plana J.C.
        • Marwick T.H.
        Use of speckle strain to assess left ventricular responses to cardiotoxic chemotherapy and cardioprotection.
        Eur Heart J Cardiovasc Imaging. 2014; 15: 324-331
        • Negishi K.
        • Negishi T.
        • Hare J.L.
        • Haluska B.A.
        • Plana J.C.
        • Marwick T.H.
        Independent and incremental value of deformation indices for prediction of trastuzumab-induced cardiotoxicity.
        J Am Soc Echocardiogr. 2013; 26: 493-498
        • Stanton T.
        • Jenkins C.
        • Haluska B.A.
        • Marwick T.H.
        Association of outcome with left ventricular parameters measured by two-dimensional and three-dimensional echocardiography in patients at high cardiovascular risk.
        J Am Soc Echocardiogr. 2014; 27: 65-73
        • Thavendiranathan P.
        • Grant A.D.
        • Negishi T.
        • Plana J.C.
        • Popovic Z.B.
        • Marwick T.H.
        Reproducibility of echocardiographic techniques for sequential assessment of left ventricular ejection fraction and volumes: application to patients undergoing cancer chemotherapy.
        J Am Coll Cardiol. 2013; 61: 77-84
        • Plana J.C.
        • Galderisi M.
        • Barac A.
        • Ewer M.S.
        • Ky B.
        • Scherrer-Crosbie M.
        • et al.
        Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging.
        J Am Soc Echocardiogr. 2014; 27: 911-939
        • Thavendiranathan P.
        • Wintersperger B.J.
        • Flamm S.D.
        • Marwick T.H.
        Cardiac MRI in the assessment of cardiac injury and toxicity from cancer chemotherapy: a systematic review.
        Circ Cardiovasc Imaging. 2013; 6: 1080-1091
        • Ky B.
        • Vejpongsa P.
        • Yeh E.T.
        • Force T.
        • Moslehi J.J.
        Emerging paradigms in cardiomyopathies associated with cancer therapies.
        Circ Res. 2013; 113: 754-764
        • Kongbundansuk S.
        • Hundley W.G.
        Noninvasive imaging of cardiovascular injury related to the treatment of cancer.
        JACC Cardiovasc Imaging. 2014; 7: 824-838
        • Halperin J.L.
        • Williams E.S.
        • Fuster V.
        COCATS 4 introduction.
        J Am Coll Cardiol. 2015; 65: 1724-1733